Johnson & Johnson Showcases Breadth of Rheumatology Innovation at ACR Convergence 2026 With 43 Presentations, Including Late-breaking Data on ICOTYDE in Psoriatic Arthritis
October 23, 2026
October 23, 2026
RARITAN, New Jersey, Oct. 23 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Johnson & Johnson showcases breadth of rheumatology innovation at ACR Convergence 2026 with 43 presentations, including late-breaking data on ICOTYDE(R) (icotrokinra) in psoriatic arthritis
Patient data from the Phase 2 study of nipocalimab in Sjogren's disease identify improvements in most core patient-relevant symptoms, with associated . . .
* * *
Johnson & Johnson showcases breadth of rheumatology innovation at ACR Convergence 2026 with 43 presentations, including late-breaking data on ICOTYDE(R) (icotrokinra) in psoriatic arthritis
Patient data from the Phase 2 study of nipocalimab in Sjogren's disease identify improvements in most core patient-relevant symptoms, with associated . . .